HighCape Capital

About The Fund

HighCape Capital is a growth equity fund established in 2013 by a consortium of seasoned executives with the primary objective of aiding innovative Life Sciences companies in their transition from early stages to successful, mature entities. They focus on investing in sectors like Biotech, Medical Devices & Hospital Services, and Oncology. Headquartered in New York, New York, HighCape Capital targets investments in the realms of Connected Health, Medical Device/Tool, and Biotechnology, with a particular emphasis on nurturing entrepreneurship, leveraging their collective experience, and working collaboratively with management teams. HighCape prides itself on its multidisciplinary team, comprising industry veterans each with over 25 years of experience in various aspects of the global Life Sciences industry. Their hands-on approach involves partnering closely with these management teams to enhance their commercial and operational strategies. HighCape's team members come from diverse backgrounds including human resources, research and development, financial and investment sectors, clinical medicine, and more. They share a passion for building companies and delivering value to limited partners and the healthcare system. HighCape’s portfolio includes companies like Elutia, Quantum-Si Incorporated, Wellinks, Cybrexa, and Alphina, showcasing their commitment to funding innovation that addresses significant medical challenges and improves outcomes. Notably, HighCape has also seen successful exits from their investments, such as the acquisitions of Cheetah Medical by Baxter International and Modifi Biosciences by Merck, as well as ZipLine Medical by Stryker, which affirm their adeptness in nurturing companies from inception to acquisition.